| Substance | Condition | Seq | Src | PMID | Dtl | Title |
| EGCG | Acute Liver Injury | 1 | PM | 36548773 | 📋 | Epigallocatechin Gallate and Glutathione Attenuate Aflatoxin B1-Induced Acute Liver Injury in Ducklings via Mitochondria-Mediated Apoptosis and the Nrf2 Signalling Pathway |
| EGCG | Alcoholic Liver Disease | 3 | PM | 34749473 | 📋 | [Effects of (+)-catechin and epigallocatechin gallate on alcoholic fatty liver in mice models] |
| EGCG | Alcoholic Liver Disease | 1 | PM | 20020850 | 📋 | Epigallocatechin Gallate, a Green Tea Phytochemical, Attenuates Alcohol-Induced Hepatic Protein and Lipid Damage |
| EGCG | Alcoholic Liver Disease | 2 | PM | 17309517 | 📋 | Epigallocatechin-3-gallate(-)protects Chang liver cells against ethanol-induced cytotoxicity and apoptosis |
| EGCG | Biliary Tract Cancer | 2 | PM | 26100134 | 📋 | The Green Tea Catechin Epigallocatechin Gallate Induces Cell Cycle Arrest and Shows Potential Synergism With Cisplatin in Biliary Tract Cancer Cells |
| EGCG | Biliary Tract Cancer | 3 | PM | 24038588 | 📋 | Quercetin and EGCG exhibit chemopreventive effects in cholangiocarcinoma cells via suppression of JAK/STAT signaling pathway |
| EGCG | Biliary Tract Cancer | 1 | PM | 19226332 | 📋 | Epigallocatechin-gallate Modulates Chemotherapy-Induced Apoptosis in Human Cholangiocarcinoma Cells |
| EGCG | Cholestasis of Pregnancy | 1 | PM | 28477356 | 📋 | Epigallocatechin-3-gallate ameliorates intrahepatic cholestasis of pregnancy by inhibiting matrix metalloproteinase-2 and matrix metalloproteinase-9 |
| EGCG | Hepatic Encephalopathy | 1 | PM | 36573265 | 📋 | Green Tea Catechin EGCG Ameliorates Thioacetamide-Induced Hepatic Encephalopathy in Rats via Modulation of the Microbiota-Gut-Liver Axis |
| EGCG | Hepatic Fibrosis | 10 | PM | 38146662 | 📋 | Epigallocatechin-3-gallate attenuates arsenic-induced fibrogenic changes in human kidney epithelial cells through reversal of epigenetic aberrations and antioxidant activities |
| EGCG | Hepatic Fibrosis | 6 | PM | 37122751 | 📋 | Inhibition of macrophages inflammasome activation via autophagic degradation of HMGB1 by EGCG ameliorates HBV-induced liver injury and fibrosis |
| EGCG | Hepatic Fibrosis | 5 | PM | 35594711 | 📋 | Epigallocatechin-3-gallate inhibits osteopontin expression and prevents experimentally induced hepatic fibrosis |
| EGCG | Hepatic Fibrosis | 4 | PM | 35586925 | 📋 | Protective effects of epigallocatechin-3-o-gallate combined with organic selenium against transforming growth factor-beta 1-induced fibrosis in LX-2 cells |
| EGCG | Hepatic Fibrosis | 3 | PM | 32253266 | 📋 | Epigallocatechin Gallate Induces Hepatic Stellate Cell Senescence and Attenuates Development of Hepatocellular Carcinoma |
| EGCG | Hepatic Fibrosis | 9 | PM | 28815679 | 📋 | (-)-Epigallocatechin-3-gallate and atorvastatin treatment down-regulates liver fibrosis-related genes in non-alcoholic fatty liver disease |
| EGCG | Hepatic Fibrosis | 2 | PM | 27935974 | 📋 | Epigallocatechin-3-Gallate Upregulates miR-221 to Inhibit Osteopontin-Dependent Hepatic Fibrosis |
| EGCG | Hepatic Fibrosis | 8 | PM | 24129183 | 📋 | Combined taurine, epigallocatechin gallate and genistein therapy reduces HSC-T6 cell proliferation and modulates the expression of fibrogenic factors |
| EGCG | Hepatic Fibrosis | 7 | PM | 23981577 | 📋 | Non-alcoholic steatohepatitis and preneoplastic lesions develop in the liver of obese and hypertensive rats: suppressing effects of EGCG on the development of liver lesions |
| EGCG | Hepatic Fibrosis | 1 | PM | 16682975 | 📋 | The Antifibrogenic Effect of (-)-Epigallocatechin Gallate Results From the Induction of De Novo Synthesis of Glutathione in Passaged Rat Hepatic Stellate Cells |
| EGCG | Hepatic Steatosis | 2 | PM | 38141939 | 📋 | Exploring the effects of epigallocatechin gallate on lipid metabolism in the rat steatotic liver during normothermic machine perfusion: Insights from lipidomics and RNA sequencing |
| EGCG | Hepatic Steatosis | 1 | PM | 18716169 | 📋 | The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice |
| EGCG | Hepatitis B | 3 | PM | 37122751 | 📋 | Inhibition of macrophages inflammasome activation via autophagic degradation of HMGB1 by EGCG ameliorates HBV-induced liver injury and fibrosis |
| EGCG | Hepatitis B | 2 | PM | 26968537 | 📋 | Epigallocatechin Gallate Inhibits Hepatitis B Virus via Farnesoid X Receptor Alpha |
| EGCG | Hepatitis B | 1 | PM | 25996297 | 📋 | Epigallocatechin-3-gallate Opposes HBV-induced Incomplete Autophagy by Enhancing Lysosomal Acidification, Which Is Unfavorable for HBV Replication |
| EGCG | Hepatitis C | 2 | PM | 30949812 | 📋 | Epigallocatechin Gallate (EGCG) and miR-548m Reduce HCV Entry Through Repression of CD81 Receptor in HCV Cell Models |
| EGCG | Hepatitis C | 1 | PM | 26202241 | 📋 | Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action |
| EGCG | Hepatotoxicity | 11 | PM | 36249942 | 📋 | Epigallocatechin gallate ameliorates tetrahydrochloride-induced liver toxicity in rats via inhibition of TGFβ / p-ERK/p-Smad1/2 signaling, antioxidant, anti-inflammatory activity |
| EGCG | Hepatotoxicity | 10 | PM | 35698845 | 📋 | Attenuation of methotrexate induced hepatotoxicity by epigallocatechin 3-gallate |
| EGCG | Hepatotoxicity | 7 | PM | 34903968 | 📋 | Preliminary Study on Hepatoprotective Effect and Mechanism of (-)-Epigallocatechin-3-gallate against Acetaminophen-induced Liver Injury in Rats |
| EGCG | Hepatotoxicity | 5 | PM | 33536712 | 📋 | Upregulation and stabilization of senescence marker protein-30 by epigallocatechin gallate against tert-butyl hydroperoxide-induced liver injury in vitro and in vivo |
| EGCG | Hepatotoxicity | 1 | PM | 33393703 | 📋 | Epigallocatechin gallate and coenzyme Q10 attenuate cisplatin-induced hepatotoxicity in rats via targeting mitochondrial stress and apoptosis |
| EGCG | Hepatotoxicity | 9 | PM | 32253266 | 📋 | Epigallocatechin Gallate Induces Hepatic Stellate Cell Senescence and Attenuates Development of Hepatocellular Carcinoma |
| EGCG | Hepatotoxicity | 8 | PM | 31945511 | 📋 | Potential Ameliorative Effects of epigallocatechin-3-gallate Against Cigarette Smoke Exposure Induced Renal and Hepatic Deficits |
| EGCG | Hepatotoxicity | 4 | PM | 31405142 | 📋 | Epigallocatechin-3-Gallate Reduces Hepatic Oxidative Stress and Lowers CYP-Mediated Bioactivation and Toxicity of Acetaminophen in Rats |
| EGCG | Hepatotoxicity | 2 | PM | 29684493 | 📋 | Evidence of Similar Protective Effects Afforded by White Tea and Its Active Component 'EGCG' on Oxidative-Stress Mediated Hepatic Dysfunction During Benzo(a)pyrene Induced Toxicity |
| EGCG | Hepatotoxicity | 6 | PM | 29029432 | 📋 | The Involvement of Nrf2 in the Protective Effects of (-)-Epigallocatechin-3-gallate (EGCG) on NaAsO 2-induced Hepatotoxicity |
| EGCG | Hepatotoxicity | 3 | PM | 26264479 | 📋 | Protective Effects of (-)-epigallocatechin-3-gallate Against Acetaminophen-Induced Liver Injury in Rats) |
| EGCG | Hepatotoxicity | 12 | PM | 24373695 | 📋 | Epigallocatechin-3-gallate (EGCG) attenuates concanavalin A-induced hepatic injury in mice |
| EGCG | Liver Cancer | 16 | PM | 37292151 | 📋 | The potential of epigallocatechin gallate in the chemoprevention and therapy of hepatocellular carcinoma |
| EGCG | Liver Cancer | 15 | PM | 36726605 | 📋 | Anti-angiogenic effect of the combination of low-dose sorafenib and EGCG in HCC-induced Wistar rats |
| EGCG | Liver Cancer | 14 | PM | 35792125 | 📋 | Epigallocatechin-3-gallate induced HepG2 cells apoptosis through ROS-Mediated AKT /JNK and p53 signaling pathway |
| EGCG | Liver Cancer | 13 | PM | 35051295 | 📋 | The Invasive Potential of Hepatoma Cells Induced by Radiotherapy is Related to the Activation of Stellate Cells and Could be Inhibited by EGCG Through the TLR4 Signaling Pathway |
| EGCG | Liver Cancer | 12 | PM | 33900350 | 📋 | Oral administration of EGCG solution equivalent to daily achievable dosages of regular tea drinkers effectively suppresses miR483-3p induced metastasis of hepatocellular carcinoma cells in mice |
| EGCG | Liver Cancer | 10 | PM | 33000276 | 📋 | Epigallocatechin gallate induces chemopreventive effects on rats with diethylnitrosamine‑induced liver cancer via inhibition of cell division cycle 25A |
| EGCG | Liver Cancer | 2 | PM | 31934166 | 📋 | ERα36 Is an Effective Target of epigallocatechin-3-gallate in Hepatocellular Carcinoma |
| EGCG | Liver Cancer | 9 | PM | 31434088 | 📋 | Synergetic Effect of EP1 Receptor Antagonist and (-)-Epigallocatechin-3-gallate in Hepatocellular Carcinoma |
| EGCG | Liver Cancer | 7 | PM | 30858692 | 📋 | Epigallocatechin-3-gallate in the Prevention and Treatment of Hepatocellular Carcinoma: Experimental Findings and Translational Perspectives |
| EGCG | Liver Cancer | 20 | PM | 29095434 | 📋 | A new molecular mechanism underlying the EGCG-mediated autophagic modulation of AFP in HepG2 cells |
| EGCG | Liver Cancer | 22 | PM | 28977833 | 📋 | Unique synergistic formulation of curcumin, epicatechin gallate and resveratrol, tricurin, suppresses HPV E6, eliminates HPV+ cancer cells, and inhibits tumor progression |
| EGCG | Liver Cancer | 19 | PM | 28817968 | 📋 | Destabilizing the interplay between miR-1275 and IGF2BPs by Tamarix articulata and quercetin in hepatocellular carcinoma |
| EGCG | Liver Cancer | 8 | PM | 27349173 | 📋 | In Vitro and in Vivo Study of epigallocatechin-3-gallate-induced Apoptosis in Aerobic Glycolytic Hepatocellular Carcinoma Cells Involving Inhibition of Phosphofructokinase Activity |
| EGCG | Liver Cancer | 3 | PM | 27058323 | 📋 | Tea Polyphenols EGCG and TF Restrict Tongue and Liver Carcinogenesis Simultaneously Induced by N-nitrosodiethylamine in Mice |
| EGCG | Liver Cancer | 1 | PM | 26386739 | 📋 | Tea Polyphenols Epigallocatechin Gallete and Theaflavin Restrict Mouse Liver Carcinogenesis Through Modulation of Self-Renewal Wnt and Hedgehog Pathways |
| EGCG | Liver Cancer | 4 | PM | 26241688 | 📋 | Epigallocatechin Gallate Hinders Human Hepatoma and Colon Cancer Sphere Formation |
| EGCG | Liver Cancer | 5 | PM | 26189955 | 📋 | Green Tea Component epigallocatechin-3-gallate Decreases Expression of Osteopontin via a Decrease in mRNA Half-Life in Cell Lines of Metastatic Hepatocellular Carcinoma |
| EGCG | Liver Cancer | 21 | PM | 25674420 | 📋 | (-)-Epigallocatechin-3-gallate suppresses hepatic preneoplastic lesions developed in a novel rat model of non-alcoholic steatohepatitis |
| EGCG | Liver Cancer | 18 | PM | 23981577 | 📋 | Non-alcoholic steatohepatitis and preneoplastic lesions develop in the liver of obese and hypertensive rats: suppressing effects of EGCG on the development of liver lesions |
| EGCG | Liver Cancer | 17 | PM | 23863984 | 📋 | Anti-metastatic and differential effects on protein expression of epigallocatechin-3-gallate in HCCLM6 hepatocellular carcinoma cells |
| EGCG | Liver Cancer | 11 | PM | 21372039 | 📋 | Preventive effects of (-)-epigallocatechin gallate on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db Mice |
| EGCG | Liver Cancer | 6 | PM | 19558547 | 📋 | (-)-Epigallocatechin Gallate Suppresses the Growth of Human Hepatocellular Carcinoma Cells by Inhibiting Activation of the Vascular Endothelial Growth Factor-Vascular Endothelial Growth Factor Receptor Axis |
| EGCG | Liver Damage | 2 | PM | 36113316 | 📋 | Epigallocatechin-3-gallate ameliorates liver injury secondary to Pseudomonas aeruginosa pneumonia |
| EGCG | Liver Damage | 1 | PM | 32570121 | 📋 | Epigallocatechin-3-gallate Protects Immunity and Liver Drug-Metabolism Function in Mice Loaded With Restraint Stress |
| EGCG | MAFLD | 15 | PM | 38607257 | 📋 | Tea Polyphenol Epigallocatechin Gallate Protects Against Nonalcoholic Fatty Liver Disease and Associated Endotoxemia in Rats via Modulating Gut Microbiota Dysbiosis and Alleviating Intestinal Barrier Dysfunction and Related Inflammation |
| EGCG | MAFLD | 14 | PM | 37447347 | 📋 | Therapeutic Activity of Green Tea Epigallocatechin-3-Gallate on Metabolic Diseases and Non-Alcoholic Fatty Liver Diseases: The Current Updates |
| EGCG | MAFLD | 10 | PM | 37025486 | 📋 | Epigallocatechin gallate alleviates high-fat diet-induced hepatic lipotoxicity by targeting mitochondrial ROS-mediated ferroptosis |
| EGCG | MAFLD | 9 | PM | 35418153 | 📋 | Epigallocatechin-3-gallate ameliorates hepatic damages by relieve FGF21 resistance and promotion of FGF21-AMPK pathway in mice fed a high fat diet |
| EGCG | MAFLD | 8 | PM | 35323719 | 📋 | Salubrious Effects of Green Tea Catechins on Fatty Liver Disease: A Systematic Review |
| EGCG | MAFLD | 7 | PM | 35119232 | 📋 | Is it possible to treat nonalcoholic liver disease using a flavanol-based nutraceutical approach? Basic and clinical data |
| EGCG | MAFLD | 6 | PM | 34356308 | 📋 | Green Tea and Epigallocatechin Gallate (EGCG) for the Management of Nonalcoholic Fatty Liver Diseases (NAFLD): Insights into the Role of Oxidative Stress and Antioxidant Mechanism |
| EGCG | MAFLD | 5 | PM | 33953830 | 📋 | Epigallocatechin-3-Gallate Alleviates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease via Inhibition of Apoptosis and Promotion of Autophagy through the ROS/MAPK Signaling Pathway |
| EGCG | MAFLD | 4 | PM | 33670347 | 📋 | Epigallocatechin-3-Gallate Dampens Non-Alcoholic Fatty Liver by Modulating Liver Function, Lipid Profile and Macrophage Polarization |
| EGCG | MAFLD | 3 | PM | 33095225 | 📋 | Green tea polyphenol epigallocatechin-3-gallate alleviates nonalcoholic fatty liver disease and ameliorates intestinal immunity in mice fed a high-fat diet |
| EGCG | MAFLD | 2 | PM | 32801462 | 📋 | Epigallocatechin-3-gallate (EGCG) attenuates non-alcoholic fatty liver disease via modulating the interaction between gut microbiota and bile acids |
| EGCG | MAFLD | 1 | PM | 32281563 | 📋 | Epigallocatechin Gallate Suppresses Inflammatory Responses by Inhibiting Toll-like Receptor 4 Signaling and Alleviates Insulin Resistance in the Livers of High-fat-diet Rats |
| EGCG | MAFLD | 12 | PM | 28815679 | 📋 | (-)-Epigallocatechin-3-gallate and atorvastatin treatment down-regulates liver fibrosis-related genes in non-alcoholic fatty liver disease |
| EGCG | MAFLD | 13 | PM | 28799714 | 📋 | Potential Biological Effects of (-)-Epigallocatechin-3-gallate on the Treatment of Nonalcoholic Fatty Liver Disease |
| EGCG | MAFLD | 11 | PM | 23515587 | 📋 | Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways |
| EGCG | Non-Alcoholic Steatohepatitis | 3 | PM | 34881283 | 📋 | Caffeine and EGCG Alleviate High-Trans Fatty Acid and High-Carbohydrate Diet-Induced NASH in Mice: Commonality and Specificity |
| EGCG | Non-Alcoholic Steatohepatitis | 2 | PM | 32875214 | 📋 | Epigallocatechin Gallate Protects Mice against Methionine-Choline-Deficient-Diet-Induced Nonalcoholic Steatohepatitis by Improving Gut Microbiota To Attenuate Hepatic Injury and Regulate Metabolism |
| EGCG | Non-Alcoholic Steatohepatitis | 1 | PM | 32688217 | 📋 | Epigallocatechin gallate but not catechin prevents nonalcoholic steatohepatitis in mice similar to green tea extract while differentially affecting the gut microbiota |
| EGCG | Non-Alcoholic Steatohepatitis | 5 | PM | 25674420 | 📋 | (-)-Epigallocatechin-3-gallate suppresses hepatic preneoplastic lesions developed in a novel rat model of non-alcoholic steatohepatitis |
| EGCG | Non-Alcoholic Steatohepatitis | 4 | PM | 23981577 | 📋 | Non-alcoholic steatohepatitis and preneoplastic lesions develop in the liver of obese and hypertensive rats: suppressing effects of EGCG on the development of liver lesions |
